































many	 applications	 in	 pharmaceutical	 industries	 and	 synthetic	 organic	 chemistry.	 In	 this
review,	we	report	a	brief	survey	of	using	the	oxetane	ring	as	versatile	precursors	in	the	total
synthesis	 of	 natural	 products.	 Many	 approaches	 such	 as	 cyclization,	 addition,	 oxidation,
reduction,	elimination,	protection	as	well	 as	 deprotection	 reactions	utilized	 to	 synthesize	of
most	important	oxetane‐containing	natural	products	involving	taxol,	(±)‐merrilactone	A,	(±)‐
oxetin,	L‐oxetanocin,	(+)‐(Z)‐laureatin	and	L‐oxetanocin	are	also	covered.	We	describe	in	this
review	 the	most	 common	 total	 synthesis	 approaches	 have	 been	 yet	 applied	 to	 synthesis	 of














One	 of	 most	 important	 example	 as	 anti‐tumor	 drug	 is	
Paclitaxel	 (Taxol)	 in	which	has	 the	oxetane	 four‐memberd	D‐
ring	can	be	essential	for	biological	activity	of	Paclitaxel	(Taxol)	
[1].	 Oxetane	 ring	 has	 also	 found	 in	 many	 other	 natural	
products	such	as	oxetin,	oxetanocin,	and	many	other	examples	
of	oxetane	containing	natural	products	(Figure	1)	[2,3].		
Thromboxane	 A2	 is	 a	 compound	 belonging	 to	 Throm‐
boxane	type	which	is	obtained	by	activated	platelets.	Half‐life	
of	Thromboxane	A2	is	very	short	about	30	seconds	in	Plasma	
[3].	Mitrephorone	A	 is	 a	 diterpenoids	having	an	oxetane	 ring	
with	 ketone	 moieties	 was	 isolated	 in	 2005	 from	Mitrephora	
Glabra	 Scheff	 by	 Oberlies	 and	 his	 co‐workers	 and	 shown	 an	
activity	as	anticancers	[4].	Maoyecrystal	I	is	a	diterpenoids	was	
isolated	from	Isidon	japonicus	and	the	structure	was	confirmed	
by	 using	 spectroscopic	 methods.	 Sun	 and	 his	 co‐workers	
reported	that	the	cytotoxity	against	K562	cells	could	be	due	to	
oxetane	 ring	 existed	 in	 the	 structure	 of	 Maoyecrystal	 I	 [5].	
Dictyoxetane	 is	 a	 diterpenoid	 was	 first	 isolated	 in	 1985	 by	
Clardy	 and	 his	 co‐workers	 from	 brown	 algae	 Dictyoatadi‐
chotoma	 in	 Indian	 Ocean.	Unusual	 structure	 of	 Dictyoxetane	
has	 attracted	 much	 attention	 to	 be	 synthesized	 [6‐10].	
Bradyoxetin	is	a	symmetrical	bis‐oxetane	ring	has	shown	to	be	
signaling	molecule	 for	Bradyrhizobium	 japonicum	 involved	 in	
symbiotic	 gene	 regulation	 [11].	We	 aim	 in	 this	 study	 to	 shed	
light	on	the	oxetane	as	useful	building	blocks	for	the	synthesis	






bacterium	 Bacilus	 megaterium	 NK84‐0218	 [12]	 Oxetanocin	
has	shown	an	activity	 to	 inhibit	 the	HIV‐virus	that	causes	the	
AIDS	disease	 [13].	Many	approaches	have	described	 the	 total	
synthesis	 of	 Oxetanocin	 [14‐19].	 Oxetanocin	 has	 attracting	
much	attention	due	to	its	high	biological	activity.	Chu	and	his	
co‐workers	have	achieved	the	 total	 synthesis	of	L‐Oxetanocin	
(Scheme	 1)	 in	 16	 steps	 and	 2.8%	 overall	 yield	 [20]	 avoiding	




to	 lactol	3	 followed	by	oxidation	of	compound	3	 to	 lactone	4.	
In	 order	 to	 get	 a	 convenient	 yield,	 this	 step	 was	 completed	






















































Mesylation	 of	 lactone	4	 to	 compound	5	 followed	 by	 ring	
contraction	to	yield	acids	6	and	7	(3:1)	(73%)	[20,23].	
The	 acids	6	 and	7	 underwent	 one‐pot	 reaction	 to	 afford	
epimeric	 thiopyridyl	 oxetanes	 8	 in	 30%	 yield.	 The	 coupling	
reaction	of	compound	8	was	resulted	the	protected	derivatives	
9	 and	10	 (2:3)	 in	 61%	 yield.	 Removing	 of	 benzyl	 protected	
group	yielded	compounds	11	and	12	and	then	hydrogenation	





Oxetin	 is	 an	 amino	 acid	 antimetabolite	 was	 isolated	 in	
1984	 from	 the	 fermentation	 broth	 of	 a	Streptomyces	 sp.	OM‐
2317	with	herbicidal	and	antibacterial	 activity	 [24,25].	 It	has	
(2R,3S)	 configuration	 as	 was	 confirmed	 by	 X‐ray	 crystallo‐
graphy.	 Total	 synthesis	 of	 Oxetin	 has	 accomplished	 by	many	
groups	 [25,26].	 Bach	 and	 his	 co‐workers	 have	 showed	 an	
efficient	method	 to	 synthesis	 of	 Oxetin	 (Rac‐1)	 in	 four	 steps	
with	an	overall	 yield	14%	[27].	They	have	been	started	 from	
available	 n‐butyl	 glyoxylate	 14	 [28]	 underwent	 a	 stereo‐
selective	Paternò‐Büchi	reaction	with	2	equivalent	of	available	
enecarbamate	 [29]	 to	 afford	 diastereomericlly	 pure	 oxetane	
15	in	yields	of	28‐35%	(Scheme	3).	
Catalytic	hydrogenolysis	was	used	to	remove	the	N‐benzyl	


























Merrilactone	A	was	 isolated	 from	 Illicium	merrillianum	 in	
2000	 by	 Fukuyama	 and	 co‐workers	 and	 has	 shown	 an	
intriguing	 neurotrophic	 activity	 in	 the	 cultures	 of	 fetal	 rat	
cortical	neurons	 [30].	The	crystal	 structure	of	Merrilactone	A	
has	identified	to	be	a	sesquiterpene	possessing	two	γ‐lactones	
as	 well	 as	 an	 oxetane	 ring.	 Due	 to	 the	 biological	 activity	 of	
Merrilactone	A,	many	synthetic	methodologies	have	applied	to	
the	 total	 synthesis	of	Merrilactone	A	 [31‐36],	 among	of	 these	
was	total	synthesis	of	(±)‐Merrilactone	A	by	Inoue	and	his	co‐




skeletons	 of	 Merrilactone	 A	 [38‐40].	 They	 were	 aimed	 to	
construct	 the	 core	 of	 meso‐diketone	 therefore,	 they	 have	
started	from	[2+2]	photocycloaddition	between	compound	19	
and	 compound	20	which	 afforded	 the	 compound	21	 [41,42].	
Compound	21	was	reducing	to	form	double	bond	and	followed	
by	 LAH‐reduction	 of	 the	 anhydride	 yielded	 meso‐diol,	 22.	
Converting	 two	hydroxyl	 groups	 into	 benzyl	 ethers	 and	 then	
dihydroxylation	has	 achieved	 to	 afford	 compound	23.	 A	 one‐
pot	reaction	[43]	of	Swern	oxidation/allylation	(compound	23,	
24	 and	 25)	 afforded	 compound	 25αα	 as	 the	 major	 isomer	
since	cis‐introduction	of	allyl	groups	occurred	from	α‐face,	this	
step	has	 accomplished	 in	 one	 step	 to	 avoid	 the	 hydrolysis	 of	
diketone	in	aqueous	workup.	Ring‐closing	metathesis	reaction	
[44‐47]	of	compound	25	yielded	bicyclo[4.2.0]octyl	system	26,	
then	 the	 reaction	 underwent	 upon	 treating	with	 Pb(OAc)4	 in	
situ	 [48]	 to	 afford	 eight	membered	 ring	27	 (Scheme	 5).	 The	
target	 compound	 28	 was	 selectively	 obtained	 from	 the	
reaction	 of	 compound	 27	with	 LiN(TMS)2	 in	 THF	 at	 ‐100	 °C	
(Scheme	 6).	 Furthermore,	 they	 have	 optimized	 reaction	










1 LiN(TMS)2,	THF,	‐110	°C 3.1	 1.0	 85
2 LiN(TMS)2,	THF,	‐40	°C 2.6	 1.0	 78
3 MgBrN(TMS)2,	Et2O,	RT 1.0	 3.0	 81
4 LiN(TMS)2,	Et3N,	toluene,	‐78	°C	 1.0	 5.1	 79















α‐Epoxide	 30	 was	 produced	 as	 a	 result	 of	 epoxidation	
reaction	 of	 compound	 28	 which	 converted	 to	 compound	31	
through	2	steps	involving	epoxide	ring	opening	with	DBU	and	
then	 IBX	 oxidation	 [49,50].	 α‐bromoacetal	 was	 added	 to	
compound	 31	 to	 yield	 compound	 32	 as	 a	 4:1	 mixture	 of	
diastereomers	(Scheme	7).	
Radical	 cyclization	 using	 Bu3SnH	 and	 BEt3	 [51,52]	
produced	a	highly	yield	of	5‐exo	cyclized	product	33	 [53‐55]	
although	 the	 steric	 effect	 around	 C9.	 They	 have	 transformed	
33α	 into	33β	 using	 acidic	 ethanol.	 The	 compound	34	which	
has	 all	 of	 the	 carbons	 of	 1	 in	 place	 was	 synthesized	 by	 the	
regioselective	silyl	enol	formation	from	33β	and	then	reacted	
with	 Eschenmoser	 reagent	 followed	 by	 m‐CPBA	 [56].	 Two	






afforded	 olefin	 37	 [59].	 The	 isomer	 benzyl	 ethers	 38	 was	


















C12	 alcohol	by	Fetizon	oxidation	 [60,61]	 afforded	bis‐lactone	
41.	 Epoxidation	 of	 bis‐lactone	 41	 using	 dimethyldioxirane	
[62,63]	 yielded	 compound	 42,	 then	 treatment	 with	 acidic	









approaches	 have	 been	 described	 the	 total	 synthesis	 of	
Laureatin	 [66‐68].	 Suzuki	 and	 his	 co‐workers	were	 reported	
the	 first	 total	 synthesis	 of	 Laureatin	 based	 on	 biosynthesis	
pathway	 which	 was	 proposed	 by	 Murai’s	 group	 [69‐71]	 as	
shown	in	Scheme	11.		
They	 have	 attempted	 to	 prepare	 laureatin	 starting	 from	
α,ά‐trans‐oxocene	 core	 43,	 the	 first	 attempt	 was	 failed	 to	
convert	 oxocene	 6	 to	 bicyclic	 skeletons	 and	 instead	 of	 that,	
tetrahydrofuran	 derivative	 was	 produced.	 The	 second	 trial	




preceded	 through	 β‐selectivity	 to	 yield	 compound	 46	 up	 to	
96%.	Upon	 treatment	 of	 compound	46	with	 aqueous	KOH	 in	
DMSO	 [72]	 led	 to	 regioselective	 4‐exo	 cyclization	 which	








































reaction	 via	 SN2	 using	 Murai’s	 procedure	 [74]	 to	 yield	
dibromide	51	(Scheme	13).	
After	 reduction	 of	 pivaloyl	 group	 in	 compound	 51	 to	
hydroxyl	group	in	96%	yield,	the	C‐C	bond	forming	proceeded	
as	 the	 following	 steps	 [75]:	 Oxidation	 using	 Dess‐Matin	
peridinane	 (93%),	 then	 reacted	with	 CBr4	 and	HMPT	 in	 THF	
(93%)	 [76]	 and	 stereoselective	 hydrogenolysis	 of	 1,1‐
dibromoalkene	by	Uenishi’s	approach	(82%)	[77],	followed	by	
sonogashira	coupling	of	the	Z‐1‐bromoalkene	(90%)	[78].	TBS	





Taxol	 [79],	 is	 anticancer	 natural	 product	 drug	 was	 first	
isolated	from	the	cytotoxic	methanolic	extract	of	the	bark	of	T.	
brevifolia	 [80].	 It	 has	 shown	 a	 very	 good	 activity	 as	 clinical	
agent	[81,82]	for	the	treatment	of	breast	[83],	ovarian	[84‐87],	
skin	 [88,89],	 lung	 [90‐92],	 and	 head	 and	 neck	 [93]	 cancers.	
Taxol	was	 approved	 in	 1993	 by	 FDA	 for	 treatment	 of	 breast	
and	ovarian	cancers	[94].	To	date,	seven	methods	was	used	in	
description	the	total	synthesis	of	taxol	[94‐103].	Nicolaou	and	
his	 co‐workers	were	 reported	 total	 synthesis	 of	 taxol	 and	 in	





Danishefsky’s	 approach	 [109]	 was	 started	 from	




hydroxyl	 group	 of	 triol	 56	 was	 selectively	 protected	 with	


























Due	 to	 the	 importance	 of	 oxetane	 ring	 as	 precursor	 for	
biologically	 active	 compounds	 and	 increasing	 use	 in	 drug	




for	 important	 oxetane‐containing	 natural	 products.	 We	 have	
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